021-51111890
购物车（）
sales@molnova.cn
KC7F2
CAS No. 927822-86-4
KC7F2 ( KC7F2 )
产品货号. M16641 CAS No. 927822-86-4
一种小分子 HIF-1α 翻译抑制剂，IC50 为 20 uM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥348 | 有现货 |
|
| 10MG | ￥421 | 有现货 |
|
| 25MG | ￥753 | 有现货 |
|
| 50MG | ￥1401 | 有现货 |
|
| 100MG | ￥2066 | 有现货 |
|
| 200MG | ￥2689 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称KC7F2
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述一种小分子 HIF-1α 翻译抑制剂，IC50 为 20 uM。
-
产品描述A small molecule HIF-1α translation inhibitor with IC50 of 20 uM; prevents the activation of HIF-target genes such as CA IX, MMP2, Endothelin 1, and Enolase 1; down regulates of HIF-1α protein synthesis by suppression of the phosphorylation of 4EBP1 and p70S6K.
-
体外实验Cell Cytotoxicity Assay Cell Line:MCF7 cells, LNZ308 cells, A549 cells, U251MG cells, LN229 cells Concentration:15–25 μM Incubation Time:0-72 hours Result:With cytotoxicity more pronounced in tumor cell lines as compared to normal cells.Cell Viability Assay Cell Line:LN229 cells Concentration:6 hours Incubation Time:0 μM, 5 μM,7.5 μM,10 μM,15 μM,20 μM,30 μM,40 μM,60 μM,80 μM Result:Decreases HIF-1α protein levels in a dose-dependent manner.
-
体内实验——
-
同义词KC7F2
-
通路Angiogenesis
-
靶点HIF/HIF Prolyl-hydroxylase
-
受体HIF-1α
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number927822-86-4
-
分子量570.3812
-
分子式C16H16Cl4N2O4S4
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 32 mg/mL
-
SMILESClC1=C(S(NCCSSCCNS(C2=C(Cl)C=CC(Cl)=C2)(=O)=O)(=O)=O)C=C(Cl)C=C1
-
化学全称Benzenesulfonamide, N,N'-(dithiodi-2,1-ethanediyl)bis[2,5-dichloro-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Narita T, et al. Clin Cancer Res. 2009 Oct 1;15(19):6128-36.
2. Guan G, et al. Cancer Lett. 2015 Feb 1;357(1):254-64.
3. Cammarata PR, et al. Mol Vis. 2015 Sep 1;21:1024-35.
产品手册
关联产品
-
M1001
M1001 是一种 HIF-2α 激动剂。
-
TAT-cyclo-CLLFVY
Selective HIF-1 dimerization inhibitor. Blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50 = 1.3 μM). Inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. Also reduces tubularization of hypoxic HUVECs.
-
Belzutifan
PT2977 是透明细胞肾细胞癌 (ccRCC) 的潜在治疗方法。 PT2977 是一种口服活性、选择性 HIF-2α 抑制剂 (IC50: 9 nM)。
